OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 7.01 EUR -0.71% Market Closed
Market Cap: 152.5m EUR
Have any thoughts about
OSE Immunotherapeutics SA?
Write Note

OSE Immunotherapeutics SA
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OSE Immunotherapeutics SA
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Operating Expenses
-€29.5m
CAGR 3-Years
7%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Operating Expenses
-€33.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Operating Expenses
-€60.5m
CAGR 3-Years
-14%
CAGR 5-Years
6%
CAGR 10-Years
-28%
G
Genfit SA
PAR:GNFT
Operating Expenses
-€58m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
-12%
Inventiva SA
PAR:IVA
Operating Expenses
-€115.7m
CAGR 3-Years
-48%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Operating Expenses
-€53.8m
CAGR 3-Years
-19%
CAGR 5-Years
-21%
CAGR 10-Years
-10%
No Stocks Found

OSE Immunotherapeutics SA
Glance View

Market Cap
152.6m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
28.11 EUR
Undervaluation 75%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Operating Expenses?
Operating Expenses
-29.5m EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Operating Expenses amounts to -29.5m EUR.

What is OSE Immunotherapeutics SA's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-7%

Over the last year, the Operating Expenses growth was 9%. The average annual Operating Expenses growth rates for OSE Immunotherapeutics SA have been 7% over the past three years , -7% over the past five years .

Back to Top